SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934

 

 

Filed by the Registrant ¨

 

Filed by a Party other than the Registrant þ

 

Check the appropriate box:

 

¨ Preliminary Proxy Statement
¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
þ Definitive Proxy Statement
¨ Definitive Additional Materials
¨ Soliciting Material Under Rule 14a-12

 

 

 

BlackRock ESG Capital Allocation Term Trust

(Name of Registrant as Specified In Its Charter)

 

Saba Capital Management, L.P.

Saba Capital Master Fund, Ltd.

Boaz R. Weinstein

Ilya Gurevich

Shavar Jeffries

Jennifer Raab

David Littlewood

David Locala

Athanassios Diplas

Alexander Vindman

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

 

 

Payment of Filing Fee (check the appropriate box):

 

 þ No fee required.
   
 ¨ Fee computed on table below per Exchange Act Rule 14a-6(i)(4) and 0-11.

 

  1) Title of each class of securities to which transaction applies:
     
     
     
  2) Aggregate number of securities to which transaction applies:
     
     

 

  3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act
Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

     
     
  4) Proposed maximum aggregate value of transaction:
     
     
     
  5) Total fee paid:
     
     
     

 

 ¨ Fee paid previously with preliminary materials.

 

 ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the
filing for which the offsetting fee was paid previously.  Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

  1) Amount Previously Paid:
     
     
     
  2) Form, Schedule or Registration Statement No.:
     
     
     
  3) Filing Party:
     
     
     
  4) Date Filed:

 

 

DATED April 21, 2024

 

BlackRock ESG Capital Allocation Term Trust

__________________________

 

PROXY STATEMENT

 

OF

Saba Capital Management, L.P.

_________________________

 

PLEASE SIGN, DATE AND MAIL THE ENCLOSED GOLD PROXY CARD TODAY

 

This proxy statement (this “Proxy Statement”) and the enclosed GOLD proxy card are being furnished by Saba Capital Management, L.P. (“Saba Capital”), Saba Capital Master Fund, Ltd. (“Saba I”), Boaz R. Weinstein (“Mr. Weinstein,” and, together with Saba Capital and Saba I, “Saba,” “we,” or “us”) and the Nominees (as defined below) named in Proposal 1 (the Nominees together with Saba, the “Participants”), in connection with the solicitation of proxies from the shareholders of BlackRock ESG Capital Allocation Term Trust, a Maryland statutory trust and closed-end management investment company registered under the Investment Company Act of 1940, as amended (the “Fund”).

 

We have submitted a proposal pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) requesting that the Board of Trustees of the Fund (the “Board”) terminate the investment management agreement between the Fund and its current investment manager (the “Shareholder Proposal”) and, because we believe that the Board needs fresh ideas and perspectives to address the Fund’s trading discount and corporate governance issues, we have nominated a slate of highly qualified and independent Nominees for election to the Board, whose election will send a strong message that the Fund’s shareholders are not satisfied with the Fund’s management and their approach to shareholder rights. In addition, we are proposing the election of and nominating the Class I Nominees (as defined below) to serve as successors to the Incumbent Trustees (as defined below).

 

We are convinced that NOW is the time to take action to close the Fund’s discount and we urge shareholders to support the Shareholder Proposal and to elect the Nominees, who we believe, if elected, would serve the best interests of all shareholders.

 

We are therefore seeking your support at the upcoming 2024 annual meeting of shareholders, including any adjournments or postponements thereof and any special meeting which may be called in lieu thereof (the “Annual Meeting”). The Fund has not yet publicly disclosed the date, time and location of the Annual Meeting. Once the Fund publicly discloses such date, time and location, Saba intends to supplement this Proxy Statement with such information and file revised definitive materials with the Securities and Exchange Commission (the “SEC”).

  

This Proxy Statement and the enclosed GOLD proxy card are first being furnished to the Fund’s shareholders on or about April 21, 2024. 

 

 

 

Saba is seeking your support at the Annual Meeting with respect to the following proposals (each, a “Proposal” and, collectively, the “Proposals”) and to consider and act upon any other business that may properly come before the Annual Meeting.

 

  Proposal   Our Recommendation
         
  1. To elect Saba’s slate of three nominees — Ilya Gurevich, Shavar Jeffries, and Jennifer Raab (the “Class II Nominees”) — to serve as Class II trustees; and Saba’s slate of four nominees — David Littlewood, David Locala, Athanassios Diplas, and Alexander Vindman (the “Class I Nominees”, and together with the Class II Nominees, the “Nominees”) — to serve as successors to Cynthia L. Egan, Lorenzo A. Flores, Stayce D. Harris and Catherine A. Lynch, who are currently serving as holdover trustees in Class I due to the Fund not having held an annual shareholder meeting in 2023 (the “Incumbent Trustees”).   FOR ALL of the Nominees
  2. To terminate the investment management agreement between the Fund and BlackRock Advisors, LLC (the “Manager”), the form of which is attached to the Fund’s Form N-2 filed with the Securities and Exchange Commission on August 17, 2021, as since amended or novated (the “Management Agreement”).   FOR
         
    To transact such other business as may properly come before the Annual Meeting.    

 

Based on the Fund’s proxy statement for the Annual Meeting (the “Fund’s Proxy Statement”), the Board is currently comprised of ten trustees divided into three classes. Each class is elected for a term of three years, with the term of one class of trustees expiring at each annual meeting of the shareholders. At the Annual Meeting, three Class II trustees are to be elected by holders of the Fund’s common shares of beneficial interest, par value $0.001 per share (the “Common Shares”), each for a three-year term expiring at the Fund’s 2027 annual meeting of shareholders, and four Class I Nominees are to be elected by holders of the Common Shares to serve as successors to the Incumbent Trustees, each for a two-year term expiring at the Fund’s 2026 annual meeting of shareholders.

 

Through this Proxy Statement and enclosed GOLD proxy card, we are soliciting proxies in support of the election of the Nominees to serve as Class II trustees and Class I trustees of the Fund, as applicable, and the approval of Proposal 2.

 

As of the close of business on the date hereof, the Participants may be deemed to “beneficially own” (such term as used in Schedule 14A within the meaning of Rule 13d-3 or Rule 16a-1 under the Exchange Act), in the aggregate, 28,552,727 Common Shares, including 1,030 Common Shares held in record name. The Fund has not yet disclosed the record date for determining shareholders entitled to notice of and to vote at the Annual Meeting (the “Record Date”) or the number of Common Shares outstanding as of the Record Date. Once the Fund publicly discloses such date and number, Saba intends to supplement this Proxy Statement with such information and file revised definitive materials with the SEC.

 

We urge you to sign, date and return the GOLD proxy card FOR ALL of the Nominees in Proposal 1 and FOR Proposal 2. By returning the GOLD proxy card, you are authorizing Saba to vote on your behalf, and if you do not indicate how you would like to vote, your vote will be counted FOR ALL of the Nominees in Proposal 1 and FORProposal 2.

 

According to the bylaws of the Fund, effective as of May 12, 2021 (the “Bylaws”), in a contested election of trustees, the qualified nominees receiving the affirmative vote of a majority of the “Shares” (as defined in the Bylaws) outstanding and entitled to vote with respect to such matter shall be elected. For Proposal 2, the affirmative vote of a 40 Act Majority (as defined below) shall be required.

 

Saba intends to deliver this Proxy Statement and the accompanying Form of GOLD Proxy Card to holders of at least the percentage of the Fund’s voting shares required under applicable law to elect the Nominees in Proposal 1 and carry the Shareholder Proposal at the Annual Meeting and otherwise intends to solicit proxies or votes from shareholders of the Fund in support of the nominations of the Nominees and the passage of the Shareholder Proposal. This proxy solicitation is being made by Saba and not on behalf of the Board or management of the Fund or any other third party. We are not aware of any other matters to be brought before the Annual Meeting other than as described herein. Should other matters be brought before the Annual Meeting, the persons named as proxies in the enclosed GOLD proxy card will vote on such matters in their discretion to the extent allowed by Rule 14a-4(c)(3) under the Exchange Act.

2 

 

 

If you have already voted using the Fund’s white proxy card, you have every right to change your vote by completing and mailing the enclosed GOLD proxy card in the enclosed pre-paid envelope or by voting via Internet or by telephone by following the instructions on the GOLD proxy card. Importantly, only the latest validly executed proxy that you submit will be counted. In addition, any proxy may be revoked at any time prior to its exercise at the Annual Meeting by following the instructions under “Can I change my vote or revoke my proxy?” in the Questions and Answers section.

 

For instructions on how to vote, including the quorum and voting requirements for the Fund and other information about the proxy materials, see the Questions and Answers section.

 

 

We urge you to promptly sign, date and return your GOLD proxy card.

 

If you have any questions or require any assistance with voting your shares, please contact our proxy solicitor, InvestorCom, toll free at (877) 972-0090 or collect at (203) 972-9300.

3 

 

 

REASONS FOR THIS PROXY SOLICITATION

 

We believe that BlackRock and the Fund’s trustees must be held accountable for the Fund’s large and persistent trading discount and its anti-shareholder governance practices.

 

Saba’s highly qualified slate of Nominees will ensure the Board has the right mix of experience to address the Fund’s critical challenges. Our Nominees possess markets experience, a deep understanding of retail investors’ needs, corporate governance expertise and capital allocation skills.

 

We recommend voting “FOR ALL” of Saba’s Nominees, and “FOR” its Shareholder Proposal.

 

 

  

4 

 

 

PROPOSAL 1: ELECTION OF CLASS II TRUSTEES AND CLASS I TRUSTEES

 

According to the Fund’s Proxy Statement, the Board is currently comprised of ten trustees divided into three classes. The members of each class are elected to serve three-year terms or until their successors have been duly elected and qualified as permitted by law with the term of office of each class ending in successive years, and according to the Fund’s Proxy Statement, there will be three Class II trustees and four Class I trustees elected by holders of Common Shares at the Annual Meeting.

 

We are soliciting proxies to elect the Class II Nominees—Ilya Gurevich, Shavar Jeffries, and Jennifer Raab—to serve as Class II trustees. Each of the Class II Nominees, if elected, will serve until the later of the date of the Fund’s 2027 annual meeting of shareholders, or until their successors have been duly elected and qualified as permitted by law.

 

We are soliciting proxies to elect the Class I Nominees—David Littlewood, David Locala, Athanassios Diplas and Alex Vindman—to serve as Class I trustees and successors to the Fund’s Incumbent Trustees. Each of the Class I Nominees, if elected, will serve until the later of the date of the Fund’s 2026 annual meeting of shareholders, or until their successors have been duly elected and qualified as permitted by law. 

On March 6, 2024, Saba filed a lawsuit against the Fund and its trustees seeking to invalidate as unlawful under the Investment Company Act of 1940, as amended (the “1940 Act”) certain bylaw provisions instituted by the Fund that require a majority of the Fund’s outstanding shares to elect trustees when a shareholder nominates trustees.1

 

Previously, on June 29, 2023, Saba I and Saba Capital filed a complaint in the United States District Court for the Southern District of New York (the “Court”) against the Fund seeking to invalidate as unlawful under the 1940 Act provisions in the Fund’s governing documents purporting to strip voting rights with respect to a shareholder’s acquisition of shares constituting as little as 10% of the Fund’s voting power (the “Vote Stripping Provisions”). On December 5, 2023, the Court granted summary judgement in favor of the Saba parties and declared the Vote Stripping Provisions to be in violation of Section 18(i) of the 1940 Act and ordered rescission of the Vote Stripping Provisions. The Fund has since appealed this ruling.

 

If all of the Class II Nominees and Class I Nominees are elected, the Nominees would comprise seven out of ten Board seats, constituting a majority of the members of the Board. There is no assurance that any of the Fund’s nominees will serve as a trustee if one or more of the Nominees are elected to the Board.

 

The age and other information related to the Nominees shown below are as of the date of this Proxy Statement.

 

Class II Nominees:

 

(1) (2) (3) (4) (5) (6)

Name, Address,

and Age

Position(s) Held

with Fund

Term of Office and Length of Time Served Principal Occupation(s) During Past 5 Years

Number of Portfolios in Fund

Complex Overseen by Trustee or Nominee for Trustee

Other Directorships Held by Trustee or Nominee for Trustee

ILYA GUREVICH

 

Address

c/o Saba Capital Management, L.P., 405 Lexington Avenue, 58th Floor, New York, New York 10174

 

Age

52

None N/A

Ilya Gurevich has served as President of G&G Retirement Planning, a retirement planning firm, since 2023 and Principal and Retirement Planner of Northeast Retirement Planning, a retirement planning firm, since 2012. Previously, Mr. Gurevich served as Principal and Trader at Dreadnought Trading, an equity derivatives trading firm, from 2007 until 2012. From 1996 to 2007, Mr. Gurevich served as an equity derivatives trader at various companies.

In 2023, Mr. Gurevich was nominated by Saba for election to the board of trustees of BlackRock Innovation and Growth Term Trust, BlackRock ESG Capital Allocation Term Trust and BlackRock California Municipal Income Trust, in connection with the 2023 annual shareholder meetings of such funds.

Mr. Gurevich became a Chess Grandmaster in 1993. In 1990, as an 18 year-old, he won the World Junior Chess Championship.

 

N/A None.

 

Mr. Gurevich earned a B.S. in Finance from New York University.

 

Mr. Gurevich’s qualifications to serve as a trustee of the Fund include his extensive experience in the investment and finance industries.

_____________________

1 Saba Capital Master Fund, Ltd. v. BlackRock ESG Capital Allocation Trust et al., No. 1:2024cv01701, S.D.N.Y. (Mar. 6, 2024).

 

5 

 

 

(1) (2) (3) (4) (5) (6)

Name, Address,

and Age

Position(s) Held

with Fund

Term of Office and Length of Time Served Principal Occupation(s) During Past 5 Years

Number of Portfolios in Fund

Complex Overseen by Trustee or Nominee for Trustee

Other Directorships Held by Trustee or Nominee for Trustee

SHAVAR JEFFRIES

 

Address

c/o Saba Capital Management, L.P., 405 Lexington Avenue, 58th Floor, New York, New York 10174

 

Age

49

None N/A

Shavar Jeffries has served as CEO of the KIPP Foundation, a non-profit organization, since 2023, a culmination of his many years as a champion for KIPP schools and educational opportunity more broadly. From 2015 to 2023, Mr. Jeffries served as the President of Education Reform Now, a non-profit organization, where he led the organization in passing well over 100 policies at the federal and state level that expanded educational opportunities for low-income students of color. Mr. Jeffries served on the board of Pzena Investment Management, Inc., an investment management firm, from 2021 to 2022. Mr. Jeffries also served as a Partner of Lowenstein Sandler LLP, a law firm, from 2014 to 2023. Prior to Lowenstein Sandler, Mr. Jeffries taught as an Associate Professor of Law at Seton Hall Law School Center for Social Justice from 2010 to 2014 and from 2004 to 2008. In between stints at Seton Hall, Mr. Jeffries served as Counsel to the Attorney General in the Office of the New Jersey Attorney General from 2008 to 2010. From 2001 to 2004, Mr. Jeffries served as a Gibbons Fellow in Public Interest Law. Prior to his time as a Gibbons Fellow, Mr. Jeffries served as an Associate at Wilmer Cutler Pickering Hale and Dorr LLP from 2000 to 2001. Prior to Wilmer, Mr. Jeffries served as Law Clerk to Judge Nathaniel R. Jones of the United States Court of Appeals for the Sixth Circuit from 1999 to 2000.

 

Mr. Jeffries served as a member of the boards of directors for MENTOR National since 2019, and prior board service on diverse organizations including Pzena Investment Management, KIPP Foundation, New Classrooms, and Duke University.

N/A None.

 

Mr. Jeffries graduated from Duke University with a B.A. in History and English in 1996 and Columbia Law School with a J.D. in 1999, where he concentrated on civil rights law and policy.

 

Mr. Jeffries’s qualifications to serve as a trustee of the Fund include his extensive experience in senior management and as a director in various businesses and leadership roles across education, politics, and law.

 

6 

 

 

(1) (2) (3) (4) (5) (6)

Name, Address,

and Age

Position(s) Held

with Fund

Term of Office and Length of Time Served Principal Occupation(s) During Past 5 Years

Number of Portfolios in Fund

Complex Overseen by Trustee or Nominee for Trustee

Other Directorships Held by Trustee or Nominee for Trustee

JENNIFER RAAB

 

Address

c/o Saba Capital Management, L.P., 405 Lexington Avenue, 58th Floor, New York, New York 10174

 

Age

67

None N/A

Jennifer Raab has served as the President and Chief Executive Officer of the New York Stem Cell Foundation, one of the world’s leading nonprofit organizations dedicated to accelerating cures for major diseases through stem cell research, since 2024. Ms. Raab is also the President Emerita of Hunter College, where she served as President from 2001 to 2023. Previously, Ms. Raab served as Chairman and Commissioner of the New York City Landmarks Preservation Commission from 1994 to 2001. From 1990 to 1994, Ms. Raab was a Litigation Associate at Paul, Weiss, Rifkind, Wharton & Garrison LLP. Prior to Paul, Weiss, Ms. Raab was a Litigation Associate at Cravath, Swaine & Moore LLP from 1985 to 1990. From 1981 to 1982, Ms. Raab served as Director of Public Affairs for the New York City Planning Commission. Ms. Raab also served as Special Projects Manager for the South Bronx Development Organization from 1979 to 1981.

 

Ms. Raab serves as a director of the Association for a Better New York Foundation and previously served as a director on the board of the Hunter College Foundation from 2001 to 2023. Also, Ms. Raab served on the boards of directors of Compuware Corporation from 2013 to 2015, One to World Foundation from 2014 to 2017, The After School Corporation from 2000 to 2017, and the United Way of New York from 2013 to 2016. Ms. Raab has also served as a member of the Advisory Boards of the National Institute of Social Sciences in 2022 and Women.NYC from 2019 to present.

 

Ms. Raab has served as a member of The Council on Foreign Relations since 2006, the Steering Committee for the Association for a Better New York since 2002, the New York Building Congress since 2009, and The Economic Club of New York since 2011.

 

Her work has garnered many awards and accolades, including her election in 2016 to the American Academy of Arts and Sciences. In 2022, she earned the Gold Honor Medal for distinguished service to society and humanity from the National Institute of Social Sciences. Ms. Raab has received additional honors from organizations including the Martina Arroyo Foundation, Albany Law School, United Way of New York City, and the Kennedy Child Study Center.

N/A None.

 

Ms. Raab received a B.A. with distinction in all subjects from Cornell University in 1977, an M.P.A. from the Woodrow Wilson School of Public and International Affairs at Princeton University in 1979, and a J.D. cum laude from Harvard Law School in 1985.

 

Ms. Raab’s qualifications to serve as a trustee of the Fund include her extensive experience in senior management and leadership roles across various institutions and businesses across multiple industries.

7 

 

 

 

 

  

Class I Nominees:

 

(1) (2) (3) (4) (5) (6)

Name, Address,

and Age

Position(s) Held

with Fund

Term of Office and Length of Time Served Principal Occupation(s) During Past 5 Years

Number of Portfolios in Fund

Complex Overseen by Trustee or Nominee for Trustee

Other Directorships Held by Trustee or Nominee for Trustee

David Littlewood

 

Address

c/o Saba Capital Management, L.P., 405 Lexington Avenue, 58th Floor, New York, New York 10174

 

Age

58

None N/A

David Littlewood was previously the co-founder and CEO of ASL Capital Markets Inc (“ASL”), a minority-owned, self-clearing, government securities broker-dealer, from August 2017 to June 2022. ASL was added to the list of Federal Reserve Bank of New York primary dealers effective April 4, 2022. ASL is a broker-dealer focused on the trading and financing of US government securities. ASL provides its trading and securities financing services to global institutional investors. As a self-clearing firm, ASL is a full netting member of the Fixed Income Clearing Corporation and has a settlement account with the Bank of New York Mellon.

 

Previously, Mr. Littlewood was the CEO of Cairn Capital North America Inc., an SEC Registered Investment Advisor, from 2011 to 2018, where he was responsible for all asset management, advisory and restructuring activities of the company. Mr. Littlewood was also the co-founder, Executive Director, and a member of the Executive Management Committee of Cairn Capital Limited (“Cairn”), an FCA-Registered Investment Advisor based in London, from 2004 to 2018. Cairn is a specialist alternative credit asset management and advisory firm with $4.5 billion of assets under management. In 2015 Mr. Littlewood and his co-founders sold a majority stake in Cairn to Mediobanca S.p.A. Prior to co-founding Cairn in 2004, Mr. Littlewood was Global Head of Structured Credit Products at the Royal Bank of Scotland plc (“RBS”), which he originally joined in 1995 as the Head of Structured Products and Financial Engineering with a specialty in all types of derivative products, including cross currency swaps, FX, inflation swaps and equity-linked products. He was responsible for overseeing all structured derivative products for both the bank’s customers and the internal finance units of the bank, including project finance, infrastructure finance, acquisition finance and leasing. He was also responsible for tax-based finance. Prior to joining the RBS, Mr. Littlewood was a Director and Head of Structuring at Hambros Bank from 1994 to 1995, where he specialized in tax-advantaged real estate, fixed-income and derivative-based transactions. Prior to joining Hambros Bank, Mr. Littlewood worked at Summit Corporate Finance Limited from 1990 to 1994 and Andersen Consulting from 1987 to 1990.

N/A None.

 

Mr. Littlewood graduated from the University of Bristol, UK in 1987 with a first-class honors degree in Chemistry. Mr. Littlewood holds the FINRA Series 17, 24, 63, 66 and 99 licenses. Mr. Littlewood is also registered with the UK Financial Conduct Authority with the CF1 (Director) and CF30 (Customer) controlled functions.

 

Mr. Littlewood’s qualifications to serve as a trustee of the Fund include his prolific experience in the financial services industry and leadership roles across various financial companies over the past 30 years.

8 

 

 

(1) (2) (3) (4) (5) (6)

Name, Address,

and Age

Position(s) Held

with Fund

Term of Office and Length of Time Served Principal Occupation(s) During Past 5 Years

Number of Portfolios in Fund

Complex Overseen by Trustee or Nominee for Trustee

Other Directorships Held by Trustee or Nominee for Trustee

DAVID LOCALA

 

Address

c/o Saba Capital Management, L.P., 405 Lexington Avenue, 58th Floor, New York, New York 10174

 

Age

57

None N/A

David Locala has more than 30 years of experience working at global companies in the financial services industry. Mr. Locala served as Managing Director and Global Head of Technology M&A at Citigroup Global Markets Inc., a global investment bank, from 2015 to 2022. Previously, Mr. Locala served as Managing Director and Co-head of Technology M&A at Deutsche Bank, a global investment bank, from 2005 to 2015.

 

Prior to joining Deutsche Bank, Mr. Locala served as a Managing Director at Lazard, a global mergers and acquisitions advisory firm from 1998 to 2005, and earlier in his career worked at Montgomery Securities from 1995 to 1998 and at Morgan Stanley from 1989 to 1993 in New York and Hong Kong.

N/A None.

 

Mr. Locala earned a Bachelor of Science in Commerce with a concentration in Finance from the University of Virginia in 1989, and a Master’s in Business Administration from Harvard Business School in 1995.

 

Mr. Locala’s qualifications to serve as a trustee of the Fund include his decades of experience working with companies in the technology sector, his leadership and extensive experience in the financial services industry, and his knowledge of financial matters.

9 

 

 

(1) (2) (3) (4) (5) (6)

Name, Address,

and Age

Position(s) Held

with Fund

Term of Office and Length of Time Served Principal Occupation(s) During Past 5 Years

Number of Portfolios in Fund

Complex Overseen by Trustee or Nominee for Trustee

Other Directorships Held by Trustee or Nominee for Trustee

Athanassios Diplas

 

Address

c/o Saba Capital Management, L.P., 405 Lexington Avenue, 58th Floor, New York, New York 10174

 

Age

59

None N/A

Dr. Athanassios Diplas served as the Principal of Diplas Advisors, LLC, a derivatives advisory company that provided expert advice on derivatives-related issues to financial institutions and law firms, from 2012 to 2017. During this time, he also served as a Senior Advisor to the Board of Directors of the International Swaps and Derivatives Association (“ISDA”) from 2012 to 2014. Previously, Dr. Diplas worked for Deutsche Bank, AG, where he served as Managing Director and Global Head of System Risk Management from 2010 to 2012; Managing Director, Global Head of Counterparty Portfolio Management Group in 2009; and Managing Director, Chief Risk Officer, and Deputy Chief Operating Officer for Global Credit Trading from 2003 to 2008. Prior to Deutsche Bank, AG, Dr. Diplas served as Vice President of Credit Derivatives at Goldman, Sachs & Co. from 1997 to 2003. From 1993 to 1995, Dr. Diplas was a Postdoctoral Research Physicist at the Center for Astrophysics & Space Sciences of the University of California, San Diego (“UCSD”). Prior to UCSD, Dr. Diplas served in the Department of Astronomy at the University of Wisconsin-Madison (“UW-Madison”) as an Assistant Scientist from 1992 to 1993 and both a Research Assistant and a Teaching Assistant from 1986 to 1992.

 

Dr. Diplas is serving on the board of BioMech Holdings LLC, a privately-held healthcare data analytics company, since 2022. Previously, Dr. Diplas served as the Co-Chair of the ISDA Industry Governance Committee and Credit Steering Committee from 2008 to 2012; a Member of the Consultative Working Group of the European Securities and Markets Authority Secondary Markets Standing Committee from 2012 to 2014; a Board Member of ICE Clear Credit CCP from 2009 to 2013; and a Risk Committee participant for two CDS CCPs from 2009 to 2012.

 

Dr. Diplas co-invented and is one of the patent holders of the credit default swap auction settlement process within ISDA (US Patent #8,078,521 B1) and led the industry effort for the development of Standard Initial Margin Model (SIMM, US Patent Application #15/143347) for uncleared transactions across all asset classes. He also co-led the related implementation effort of the Working Group on Margin Requirements, an initiative jointly run by the Basel Committee on Banking Supervision and the International Organization of Securities Commissions.

N/A None.
           

 

Dr. Diplas received a B.S. with distinction in physics from Aristotle University of Thessaloniki in 1986; an M.S. and a Ph.D. in Astronomy from UW-Madison in 1988 and 1992, respectively; and an M.B.A. from The Wharton School at the University of Pennsylvania in 1997.

 

Dr. Diplas’s qualifications to serve as a trustee of the Fund include his 20 years in the financial services industry with a focus on derivatives, risk, and credit investing as well as his pivotal role in safeguarding markets through industry-wide committee work both in the United States and in Europe.

10 

 

 

(1) (2) (3) (4) (5) (6)

Name, Address,

and Age

Position(s) Held

with Fund

Term of Office and Length of Time Served Principal Occupation(s) During Past 5 Years

Number of Portfolios in Fund

Complex Overseen by Trustee or Nominee for Trustee

Other Directorships Held by Trustee or Nominee for Trustee

alexander vindman

 

Address

c/o Saba Capital Management, L.P., 405 Lexington Avenue, 58th Floor, New York, New York 10174

 

Age

48

None N/A

Dr. Alexander Vindman, a retired U.S. Army Lieutenant Colonel, has served as the President of the Here Right Matters Foundation, a 501(c)(3) nonprofit organization that is focused on helping Ukraine win its war with Russia and rebuild afterwards, since 2023 and as the Founder and Director of the Institute for Informed American Leadership, a national security think tank, since 2022. Previously, Dr. Vindman was the director for Eastern Europe, the Caucasus, and Russia on the White House’s National Security Council from 2018 to 2020. Prior to the National Security Council, he served as the Political-Military Affairs Officer for Russia for the Chairman of the Joint Chiefs of Staff from 2015 to 2018 and as an attaché at the U.S. Embassies in Moscow, Russia and Kyiv, Ukraine from 2008 to 2015.

 

Dr. Vindman has served as a Senior Fellow at the Foreign Policy Institute at the Johns Hopkins School of Advanced International Studies since 2020, a Hauser Leader at the Center for Public Leadership at Harvard University’s Kennedy School of Government since 2022, an Executive Board Member of the Renew Democracy Initiative since 2020, a Senior Fellow at the Kettering Foundation since 2023, and a Senior Advisor for VoteVets since 2021.

 

Dr. Vindman is a published author with his 2021 New York Times bestselling memoir, Here, Right Matters, detailing, amongst other things, how he became a chief witness in former President Donald Trump’s first impeachment trial.

 

Dr. Vindman’s military awards include two Legions of Merit and the Purple Heart, having sustained wounds in an IED attack during the Iraq War.

N/A None.

 

Dr. Vindman received a B.A. from the State University of New York at Binghamton in 1999, an M.A. in Russian, Eastern European, and Central Asian Studies from Harvard University in 2011, an MA in International Affairs from Johns Hopkins School of Advanced International Studies in 2021, and a Ph.D. from the Johns Hopkins School of Advanced International Studies in 2022.

 

Dr. Vindman’s qualifications to serve as a trustee of the Fund include his academic and professional accomplishments, his notable experience as a geopolitical strategist, and his renown for upholding proper governance principles through ethical leadership and accountability.

 

 

The Nominees do not currently hold, and have not at any time held, any position with the Fund. The Nominees do not oversee any portfolios in the Fund’s Fund Complex (as defined in the 1940 Act).

 

11 

 

 

As of the date of this Proxy Statement, the dollar range of the equity securities of the Fund beneficially owned by the Nominees and the aggregate range of equity securities in all funds to be overseen by the Nominees, are as follows:

 

Name of Nominee Dollar Range of Equity Securities in the Fund Aggregate Dollar Range of Equity Securities in All Companies to be Overseen by the Nominee in a Family of Investment Companies
Ilya Gurevich None None
Shavar Jeffries None None
Jennifer Raab None None
David Littlewood None None
David Locala None None
Athanassios Diplas None None
Alexander Vindman None None

 

None of the organizations or corporations referenced above is a parent, subsidiary, or other affiliate of the Fund. We believe that, if elected, the Nominees will be considered independent trustees of the Fund under (i) the pertinent listing standards of the New York Stock Exchange, and (ii) paragraph (a)(1) of Item 407 of Regulation S-K. In addition, we believe that the Nominees are not and will not be “interested persons” of the Fund within the meaning of section 2(a)(19) of the 1940 Act.

We refer shareholders to the Fund’s Proxy Statement for the names, background, qualifications and other information concerning the Fund’s trustee nominees. The Fund’s Proxy Statement and form of proxy will become available free of charge on the SEC’s website at www.sec.gov.

12 

 

Each of the Nominees has entered into a nominee agreement (the “Nominee Agreements”) pursuant to which Saba Capital has agreed to defend and indemnify the Nominees against, and with respect to, any losses that may be incurred by such Nominee in the event he or she becomes a party to litigation based on his nomination as a candidate for election to the Board and the solicitation of proxies in support of his election. If elected or appointed, the Nominees will be entitled to such compensation from the Fund as is consistent with the Fund’s practices for services of non-employee trustees. The Nominees will not receive any compensation from Saba for their services as trustees of the Fund if elected or for any other reason.

The Nominees have agreed to being nominated as nominees in this Proxy Statement and have confirmed their willingness to serve on the Board if elected. We do not expect that the Nominees will be unable to stand for election, but, in the event that a Saba Nominee is unable to or for good cause will not serve, the Common Shares represented by the GOLD proxy card will be voted for a substitute candidate selected by Saba, a right that Saba has reserved in its nomination notice. In the case of any of the foregoing, Saba will give prompt written notice to the Fund if it chooses to nominate any such additional or substitute nominee and Saba will file and deliver supplemental proxy materials, including a revised proxy card, disclosing the information relating to such additional person that is required to be disclosed in solicitations for proxies for the election of directors pursuant to Section 14 of the Exchange Act. If Saba determines to add nominees, whether because the Fund expands the size of the Board subsequent to the date of this Proxy Statement or for any other reason, Saba will supplement this Proxy Statement.

 

Vote Required.

According to the Bylaws, in a contested election of trustees, the qualified nominees receiving the affirmative vote of a majority of the Common Shares outstanding and entitled to vote with respect to such matter shall be elected.

 

Abstentions will be counted for purposes of determining whether a quorum is present. Therefore, abstentions will have the same effect as votes “against” Proposal 1.

 

We urge you to sign and return our GOLD proxy card. If you have already voted using the Fund’s white proxy card, you have every right to change your vote by completing and mailing the enclosed GOLD proxy card in the enclosed pre-paid envelope or by voting via Internet or by telephone by following the instructions on the GOLD proxy card. Only the latest validly executed proxy that you submit will be counted; any proxy may be revoked at any time prior to its exercise at the Annual Meeting by following the instructions under “Can I change my vote or revoke my proxy?” If you have any questions or require any assistance with voting your shares, please contact our proxy solicitor, InvestorCom, toll free at (877) 972-0090 or collect at (203) 972-9300.

 

 

 We Recommend a Vote FOR ALL of the Nominees for election at the Annual Meeting on the GOLD proxy card.

13 

 

 

PROPOSAL 2: TERMINATE THE MANAGEMENT AGREEMENT BETWEEN THE FUND AND THE MANAGER

 

The Record Holder is seeking to terminate the Management Agreement in accordance with the provisions of Section 12 thereof. Under Section 12 of the Management Agreement and pursuant to the 1940 Act, the Management Agreement may be terminated at any time, by either the trustees of the Fund or a majority of the outstanding securities of the Fund upon sixty (60) days’ prior written notice to the Manager.

 

Rule 15a-4 under the 1940 Act provides a temporary exemption to the approval requirements of an investment management agreement, in the event that a prior advisory contract is terminated, which allows the Board (including a majority of the independent trustees) to approve an interim investment management contract. Such an interim contract is required to be approved within ten business days after the date that the termination of the prior advisory contract becomes effective, with the compensation received under the interim contract to be no greater than the compensation the adviser would have received under the previous contract. The Board would then have 150 days to obtain shareholder approval for that new investment management contract at a subsequent meeting of shareholders. Although the failure to approve a permanent investment management agreement could potentially require the Fund to become internally managed, we believe any reasonably designed process to select a new manager would identify a number of suitable, alternative advisers willing to advise the Fund on attractive terms.

 

If the proposal to terminate the Management Agreement is approved by shareholders, the Board will have the ability to appoint an interim manager and/or long-term manager of its choosing, the latter being subject to shareholder approval. In such instance, Saba Capital would stand ready to assist in any way it can to help the Board ensure that a capable manager is installed, and may at such time offer its services to the Board to act as an interim or long-term manager to the Fund and/or recommend to the Board various third-party manager candidates for the Board to consider at its discretion. For the avoidance of doubt, termination of the Management Agreement will not require the Fund to pursue any agreement with Saba relating to the appointment of a new manager, be it Saba Capital or any other potential manager replacement, and shareholders will have the final say on the appointment of any long-term manager.

 

Accordingly, shareholders are being asked to vote on the following resolution:

 

“RESOLVED, that the investment management agreement between BlackRock ESG Capital Allocation Term Trust (the “Trust”) and BlackRock Advisors, LLC, the form of which is attached to the Trust’s Form N-2, filed with the Securities and Exchange Commission on August 17, 2021, as since amended or novated (the “Management Agreement”), shall be terminated by the Trust, pursuant to the right of stockholders as embodied in Section 12 of the Management Agreement and Section 15(a)(3) of the Investment Company Act of 1940, such termination to be effective no more than sixty days following the date hereof.”

 

Vote Required.

The approval of Proposal 2 requires the affirmative vote of a “majority of the outstanding voting securities” of the Fund, which is defined under the 1940 Act to be the lesser of: (i) 67% or more of shares of the voting securities present at such meeting, if the holders of more than 50% of the outstanding shares of voting securities are present or represented by proxy, or (ii) more than 50% of the outstanding shares of voting securities (a “40 Act Majority”). Abstentions will have the same effect as votes “against” Proposal 2.

 

 

 We Recommend a Vote FOR Proposal 2 on the GOLD proxy card.

 

14 

 

 

 


QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND THE ANNUAL MEETING

 

Who is entitled to vote?

 

 

Only holders of Common Shares at the close of business on the Record Date are entitled to notice of and to vote at the Annual Meeting. Shareholders who sold their Common Shares before the Record Date (or acquire them without voting rights after the Record Date) may not vote such Common Shares. Shareholders of record on the Record Date will retain their voting rights in connection with the Annual Meeting even if they sell such Common Shares after the Record Date (unless they also transfer their voting rights as of the Record Date).

 

How do I vote my shares?

 

 

Common Shares held in record name. If your Common Shares are registered in your own name, please vote today by signing, dating and returning the enclosed GOLD proxy card in the postage-paid envelope provided. Execution and delivery of a proxy by a record holder of Common Shares will be presumed to be a proxy with respect to all shares held by such record holder unless the proxy specifies otherwise.

 

Common Shares beneficially owned or held in “street” name. If you hold your Common Shares in “street” name with a broker, bank, dealer, trust company or other nominee, only that nominee can exercise the right to vote with respect to the Common Shares that you beneficially own through such nominee and only upon receipt of your specific instructions. Accordingly, it is critical that you promptly give instructions to your broker, bank, dealer, trust company or other nominee to vote FOR the Nominees and FOR the Shareholder Proposal. Please follow the instructions to vote provided on the enclosed GOLD voting instruction form. If your broker, bank, dealer, trust company or other nominee provides for proxy instructions to be delivered to them by telephone or Internet, instructions will be included on the enclosed GOLD voting instruction form. We urge you to confirm in writing your instructions to the person responsible for your account and provide a copy of those instructions by emailing them to Saba@investor-com.com or mailing them to Saba Capital Management, L.P., c/o InvestorCom, 19 Old Kings Highway S., Suite 130, Darien, CT 06820, so that we will be aware of all instructions given and can attempt to ensure that such instructions are followed.

 

Note: Common Shares represented by properly executed GOLD proxy cards will be voted at the Annual Meeting as marked and, in the absence of specific instructions, FOR ALL of Saba’s Nominees and FOR the Shareholder Proposal.

 

How should I vote on the Proposals?

 

 

We recommend that you vote your shares on the GOLD proxy card as follows:

“FOR ALL” of the Nominees standing for election to the Board named in this Proxy Statement (Proposal 1); and

“FOR” the termination of the Management Agreement between the Fund and the Manager (Proposal 2).

The Participants intend to vote all of their Common Shares “FOR ALL” of the Nominees in Proposal 1 and “FOR” Proposal 2, except for a small percentage of Common Shares owned by certain of the Saba Entities (as defined in Annex I) that, pursuant to internal proxy voting policies, will be echo-voted (i.e. meaning they will be voted in the same proportion as the votes of all other shareholders).

Each Proposal is a separate proposal. You may vote on each separately and in accordance with your discretion.

How many shares must be present to hold the Annual Meeting?

 

 

According to the Bylaws, the holders of a majority of the Common Shares entitled to vote on any matter at a meeting present in person or by proxy shall constitute a quorum at the Annual Meeting. Abstentions are treated as votes present for purposes of determining a quorum. For information on the treatment of broker non-votes, if any, in connection with the Annual Meeting, please see the Fund’s Proxy Statement.

 

15 

 

What vote is needed to approve the Proposals?

 

Proposal 1 – Election of Class II Trustees and Class I Trustees. According to the Bylaws, in a contested election of trustees, the qualified nominees receiving the affirmative vote of a majority of the Common Shares outstanding and entitled to vote with respect to such matter shall be elected. Abstentions will be counted as votes “against” a nominee in Proposal 1.

THE ONLY WAY TO SUPPORT ALL OF THE NOMINEES FOR ELECTION AT THE ANNUAL MEETING IS TO SUBMIT YOUR VOTING INSTRUCTIONS “FOR ALL” OF THE NOMINEES ON THE ENCLOSED GOLD PROXY CARD. PLEASE DO NOT SIGN OR RETURN A WHITE PROXY CARD FROM THE FUND, EVEN IF YOU INSTRUCT TO “ABSTAIN” YOUR VOTES. DOING SO WILL REVOKE ANY PREVIOUS VOTING INSTRUCTIONS YOU PROVIDED ON THE GOLD PROXY CARD.

 

Proposal 2 – Termination of the Management Agreement. The approval of Proposal 2 requires the affirmative vote of a 40 Act Majority. Abstentions will have the same effect as votes “against” Proposal 2.

 

What should I do if I receive a proxy card from the Fund?

 

 

You may receive proxy solicitation materials from the Fund, including an opposition proxy statement and a white proxy card. We are not responsible for the accuracy of any information contained in any proxy solicitation materials used by the Fund or any other statements that it may otherwise make.

 

We recommend that you discard any proxy card that may be sent to you by the Fund. Voting “ABSTAIN” or “AGAINST” on its white proxy card is not the same as voting for the Nominees or the Shareholder Proposal because a vote on the Fund’s white proxy card will revoke any previous voting instructions that you submitted on the GOLD proxy card. If you have already voted using the Fund’s white proxy card, you have every right to change your vote by using the enclosed GOLD proxy card by signing, dating and returning the enclosed GOLD proxy card in the postage-paid envelope provided. Only the latest validly executed proxy that you submit will be counted; any proxy may be revoked at any time prior to its exercise at the Annual Meeting by following the instructions below under “Can I change my vote or revoke my proxy?”

 

If you have any questions or require any assistance with voting your shares, please contact our proxy solicitor, InvestorCom. Shareholders may call toll free at (877) 972-0090 or collect at (203) 972-9300.

 

Can I change my vote or revoke my proxy?

 

 

If you are the shareholder of record, you may change your proxy instructions or revoke your proxy at any time before your proxy is voted at the Annual Meeting. Proxies may be revoked by any of the following actions:

·signing, dating and returning the enclosed GOLD proxy card in the postage-paid envelope provided or signing, dating and returning a white proxy card (the latest dated proxy is the only one that counts);
·delivering a written revocation to the secretary of the Fund at 50 Hudson Yards, New York, NY 10001; or
·attending the Annual Meeting and voting by ballot in person (although attendance at the Annual Meeting will not, by itself, revoke a proxy).

 

If your shares are held in a brokerage account by a broker, bank or other nominee, you should follow the instructions provided by your broker, bank or other nominee. If you attend the Annual Meeting and you beneficially own Common Shares but are not the record owner, your mere attendance at the Annual Meeting WILL NOT be sufficient to revoke any previously submitted proxy card. You must have written authority from the record owner to vote your shares held in its name at the meeting in the form of a “legal proxy” issued in your name from the bank, broker or other nominee that holds your shares. If you have any questions or require any assistance with voting your shares, please contact our proxy solicitor, InvestorCom, toll free at (877) 972-0090 or collect at (203) 972-9300.

 

IF YOU HAVE ALREADY VOTED USING THE FUND’S WHITE PROXY CARD, WE URGE YOU TO REVOKE IT BY FOLLOWING THE INSTRUCTIONS ABOVE. Although a revocation is effective if delivered to the Fund, we request that a copy of any revocation be mailed to Saba Capital Management, L.P., c/o InvestorCom, 19 Old Kings Highway S., Suite 130, Darien, CT 06820, so that we will be aware of all revocations.

 

16 

 

 

Who is making this Proxy Solicitation and who is paying for it?

 

 

The solicitation of proxies pursuant to this proxy solicitation is being made by the Participants. Proxies may be solicited by mail, facsimile, telephone, telegraph, Internet, in person or by advertisements. Saba will solicit proxies from individuals, brokers, banks, bank nominees and other institutional holders. Saba will request banks, brokerage houses and other custodians, nominees and fiduciaries to forward all solicitation materials to the beneficial owners of the Common Shares they hold of record. Saba will reimburse these record holders for their reasonable out-of-pocket expenses in so doing. It is anticipated that certain regular employees of Saba will also participate in the solicitation of proxies in support of the Nominees and the Shareholder Proposal. Such employees will receive no additional consideration if they assist in the solicitation of proxies.

 

Saba has retained InvestorCom to provide solicitation and advisory services in connection with this solicitation. InvestorCom will be paid a fee not to exceed $20,000 based upon the campaign services provided. In addition, Saba will advance costs and reimburse InvestorCom for reasonable out-of-pocket expenses and will indemnify InvestorCom against certain liabilities and expenses, including certain liabilities under the federal securities laws. InvestorCom will solicit proxies from individuals, brokers, banks, bank nominees and other institutional holders. It is anticipated that InvestorCom will employ approximately 25 persons to solicit the Fund’s shareholders as part of this solicitation. InvestorCom does not believe that any of its owners, managers, officers, employees, affiliates or controlling persons, if any, is a “participant” in this proxy solicitation.

 

The entire expense of soliciting proxies is being borne by Saba. Costs of this proxy solicitation are currently estimated to be approximately $150,000. We estimate that through the date hereof, Saba’s expenses in connection with the proxy solicitation are approximately $75,000. Saba does not intend to seek reimbursement of these costs from the Fund.

 

What is Householding of Proxy Materials?

 

 

 

The SEC has adopted rules that permit companies and intermediaries (such as brokers and banks) to satisfy the delivery requirements for proxy statements and annual reports with respect to two or more shareholders sharing the same address by delivering a single proxy statement addressed to those shareholders. Some banks and brokers with account holders who are shareholders of the Fund may be householding our proxy materials.

Once you have received notice from your bank or broker that it will be householding communications to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement and annual report, please notify your bank or broker and direct your request to the Fund at 50 Hudson Yards, New York, NY 10001, or by calling toll free at 1-800-882-0052.

Because Saba has initiated a contested proxy solicitation, we understand that banks and brokers with account holders who are shareholders of the Fund will not be householding our proxy materials.

 

Where can I find additional information concerning the Fund?

 

 

Pursuant to Rule 14a-5(c) promulgated under the Exchange Act, we have omitted from this Proxy Statement certain disclosure required by applicable law to be included in the Fund’s definitive proxy statement in connection with the Annual Meeting. Such disclosure includes information regarding securities of the Fund beneficially owned by the Fund’s trustees, nominees and management; the Fund’s investment manager and administrator; the Audit Committee of the Board; certain shareholders’ beneficial ownership of more than 5% of the Fund’s voting securities; information concerning the Fund’s trustees; information concerning executive compensation; and information concerning the procedures for submitting shareholder proposals and trustee nominations intended for consideration at the 2025 annual meeting of shareholders and for consideration for inclusion in the proxy materials for that meeting. We take no responsibility for the accuracy or completeness of any information that we expect to be contained in the Fund’s definitive proxy statement. Except as otherwise noted herein, the information in this Proxy Statement concerning the Fund has been taken from or is based upon documents and records on file with the SEC and other publicly available information.

 

This Proxy Statement and all other solicitation materials in connection with this proxy solicitation will be available on the internet, free of charge, on the SEC’s website at https://www.sec.gov/edgar. The Edgar file number for the Fund is 811-23701.

17 

 

 

CONCLUSION

 

We urge you to carefully consider the information contained in this Proxy Statement and then support our efforts by signing, dating and returning the enclosed GOLD proxy card today.

 

Thank you for your support,

 

Saba Capital Management, L.P.

Saba Capital Master Fund, Ltd.

Boaz R. Weinstein

Ilya Gurevich

Shavar Jeffries

Jennifer Raab

David Littlewood

David Locala

Athanassios Diplas

Alexander Vindman

 

April 21, 2024

 

 

 

18 

 

 

ANNEX I: INFORMATION ON THE PARTICIPANTS

 

 

Beneficial Ownership and Other Information

 

This proxy solicitation is being made by the Participants. As of the date of this Proxy Statement, the Participants may be deemed to “beneficially own” (such term as used in Schedule 14A within the meaning of Rule 13d-3 or Rule 16a-1 under the Exchange Act for the purposes of this Annex I) 28,552,727 Common Shares in the aggregate, representing 28.02% of the outstanding Common Shares. The percentage used herein is based upon 101,893,121 Common Shares outstanding as of December 31, 2023, as disclosed in the Fund’s Annual Report for the fiscal year ended December 31, 2023 filed with the SEC on March 6, 2024. Of the 28,552,727 Common Shares owned in the aggregate by the Participants, such Common Shares may be deemed to be beneficially owned as follows: (a) 28,552,727 Common Shares (including 1,030 Common Shares held in record name by Saba I) may be deemed to be beneficially owned by Saba Capital by virtue of its status as the investment manager of various funds and accounts, such funds and accounts, the (“Saba Entities”); and (b) 28,552,727 Common Shares (including 1,030 Common Shares held in record name by Saba I) may be deemed to be beneficially owned by Mr. Weinstein by virtue of his status as the principal of Saba Capital.

 

As of the date of this Proxy Statement, none of the Nominees beneficially own any Common Shares or any other securities of the Fund.

 

Ms. Raab and Mr. Locala, each a Nominee, may be deemed to, respectively, own >$120,000 worth of stock in funds that may be deemed affiliates of the Fund.

 

The principal business of Saba Capital is to serve as investment manager to the Saba Entities. The principal business of Saba I is to serve as a private investment fund. The principal business of Mr. Weinstein is investment management and serving as the principal of Saba Capital. The principal business of the Saba Entities is to invest in securities.

 

The business address of each member of Saba and the Saba Entities is 405 Lexington Avenue, 58th Floor, New York, New York 10174.

 

The principal occupation and business address of each of the Nominees are disclosed in the section of this Proxy Statement titled “PROPOSAL 1: ELECTION OF CLASS II TRUSTEES AND CLASS I TRUSTEES”.

 

Unless otherwise noted as shares held in record name by the Saba Entities, the Common Shares held by the Saba Entities are held in commingled margin accounts, which may extend margin credit to such parties from time to time, subject to applicable federal margin regulations, stock exchange rules and credit policies. In such instances, the positions held in the margin account are pledged as collateral security for the repayment of debit balances in the account. The margin accounts bear interest at a rate based upon the broker’s call rate from time to time in effect. Because other securities are held in the margin accounts, it is not possible to determine the amounts, if any, of margin used to purchase the Common Shares reported herein since margin may have been attributed to such other securities and since margin used is not disclosed on an individual per-security basis.

19 

 



Disclaimer

 

Except as set forth in this Proxy Statement (including the Appendices hereto), (i) within the past 10 years, no Participant in this solicitation has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors); (ii) no Participant and no associate or “Immediate Family Member” (as defined in Item 22 of Schedule 14A under the Exchange Act (“Item 22”)) of any Participant, is a record owner or direct or indirect beneficial owner of any securities of the Fund, any parent or subsidiary of the Fund, any investment adviser, principal underwriter, or “Sponsoring Insurance Company” (as defined in Item 22) of the Fund, or in any registered investment companies overseen or to be overseen by the Participant within the same “Family of Investment Companies” (as defined in Item 22) that directly or indirectly controls, is controlled by or is under common control with an investment adviser, principal underwriter, or Sponsoring Insurance, or affiliated person of the Fund; (iii) no Participant in this solicitation directly or indirectly beneficially owns any securities of the Fund which are owned of record but not beneficially; (iv) no Participant in this solicitation has purchased or sold any securities of the Fund or the Fund’s investment adviser within the past two years, nor from either entity’s “Parents” or “Subsidiaries” (as defined in Item 22), (v) no Participant has any “family relationship” for the purposes of Item 22 whereby a family member is an “Officer” (as defined in Item 22), trustee (or person nominated to become an Officer or trustee), employee, partner, or copartner of the Fund, the Fund’s investment adviser and/or a principal underwriter of any of the foregoing, or any Subsidiary or other potential affiliate of any of the foregoing; (vi) no part of the purchase price or market value of the securities of the Fund owned by any Participant in this solicitation is represented by funds borrowed or otherwise obtained for the purpose of acquiring or holding such securities; (vii) no Participant in this solicitation is, or within the past year was, a party to any contract, arrangements or understandings with any person with respect to any securities of the Fund, including, but not limited to, joint ventures, loan or option arrangements, puts or calls, guarantees against loss or guarantees of profit, division of losses or profits, or the giving or withholding of proxies; (viii) no associate of any Participant in this solicitation owns beneficially, directly or indirectly, any securities of the Fund; (ix) no Participant in this solicitation owns beneficially, directly or indirectly, any securities of any parent or subsidiary of the Fund; (x) within the last five years, no Nominee has had any arrangement or understanding with any other person pursuant to which he was selected to be a nominee for election as a trustee to the Fund other than the Nominee Agreements described herein; (xi) no Participant and no Immediate Family Member of any Participant in this solicitation or any of his or its associates was a party to, or had a direct or indirect material relationship in, any transaction or series of similar transactions since the beginning of the Fund’s last fiscal year, or is a party to any currently proposed transaction, or series of similar transactions in which the amount involved exceeds $120,000 and for which any of the following was or is a party: (a) the Fund or any of its subsidiaries; (b) an Officer of the Fund; (c) an investment company, or a person that would be an investment company but for the exclusions provided by sections 3(c)(1) and 3(c)(7) of the 1940 Act, having the same investment adviser, principal underwriter, or Sponsoring Insurance Company as the Fund or having an investment adviser, principal underwriter, or Sponsoring Insurance Company that directly or indirectly controls, is controlled by or is under common control with the investment adviser, principal underwriter, or Sponsoring Insurance Company of the Fund; (d) an investment adviser, principal underwriter, Sponsoring Insurance Company, or affiliated person of the Fund; (e) any Officer or any person directly or indirectly controlling, controlled by, or under common control with any investment adviser, principal underwriter, Sponsoring Insurance Company, or affiliated person of the Fund; (f) an Officer of an investment adviser, principal underwriter, or Sponsoring Insurance Company of the Fund or (g) an Officer of a person directly or indirectly controlling, controlled by, or under common control with an investment adviser, principal underwriter or Sponsoring Insurance Company of the Fund; (xii) during the last five years, no Participant and no Immediate Family Member of any Participant has had a position or office with: (a) the Fund; (b) an investment company, or a person that would be an investment company but for the exclusions provided by Sections 3(c)(1) and 3(c)(7) of the 1940 Act, having the same investment adviser, principal underwriter, or Sponsoring Insurance Company as the Fund or having an investment adviser, principal underwriter, or Sponsoring Insurance Company that directly or indirectly controls, is controlled by, or is under common control with an investment adviser, principal underwriter, or Sponsoring Insurance Company of the Fund or (c) an investment adviser, principal underwriter, Sponsoring Insurance Company or affiliated person; (xiii) no Participant in this solicitation or any of his or its associates has any arrangement or understanding with any person with respect to any future employment by the Fund or its affiliates, or with respect to any future transactions to which the Fund or any of its affiliates will or may be a party; (xiv) no Participant in this solicitation has a substantial interest, direct or indirect, by securities holdings or otherwise, in any matter to be acted on at the Annual Meeting; (xv) there are no material pending legal proceedings to which any Nominee or any of his or her associates is a party adverse to the Fund or, to the best of Saba’s knowledge after reasonable investigation, any affiliated person of the Fund, nor does any Nominee have a material interest in such proceedings that is adverse to the Fund or, to the best of the Saba’s knowledge after reasonable investigation, any affiliated person of the Fund; (xvi) since the beginning of the last two completed fiscal years, no Participant (and no Immediate Family Member of a Participant) has served on the board of directors or trustees of a company or trust where an Officer of an investment adviser, principal underwriter, or Sponsoring Insurance Company of the Fund, or any person directly or indirectly controlling, controlled by, or under common control with any of those, serves on the board of directors or trustees and (xvii) no Participant has withheld information that is required to be disclosed under the following Items under Regulation S-K under the Exchange Act: Item 401(f) with respect to involvement in certain legal proceedings, Item 401(g) with respect to promoters and control persons, and Item 405 with respect to beneficial ownership and required filings.

 

20 

 

 

 

Transactions by the Participants with respect to the Fund’s securities

 

The following tables set forth all transactions effected during the past two years by Saba, by virtue of Saba Capital’s direct and indirect control of the Saba Entities, with respect to securities of the Fund. The Common Shares reported herein are held in either cash accounts or margin accounts in the ordinary course of business. Unless otherwise indicated, all transactions were effected on the open market.

 

Common Shares:

 

Saba Capital, in its capacity as investment manager of the Saba Entities (including Saba I)

 

Date Side Common   08/29/2022 Buy  55,751   11/16/2022 Buy 106,947
    Shares   08/30/2022 Buy  30,952   11/18/2022 Buy  30,239
05/03/2022 Buy  99,301   08/31/2022 Buy  2,388   11/22/2022 Buy  10,000
05/04/2022 Buy  76,073   09/06/2022 Buy  99,343   11/28/2022 Buy  55,728
05/05/2022 Buy  52   09/07/2022 Buy  35,843   11/29/2022 Buy  48,638
05/06/2022 Buy  3,917   09/08/2022 Buy  26,264   11/30/2022 Buy  75,617
05/09/2022 Buy  6,487   09/09/2022 Buy  89,007   12/01/2022 Buy  28,110
05/10/2022 Buy  74,316   09/12/2022 Buy  84,720   12/02/2022 Buy  85,299
05/11/2022 Buy  55,702   09/14/2022 Buy  67,776   12/05/2022 Buy  17,400
05/12/2022 Buy  1,412   09/15/2022 Buy  113,418   12/06/2022 Buy  36,170
05/17/2022 Buy  7,532   09/16/2022 Buy  73,041   12/07/2022 Buy  2,341
06/01/2022 Buy  40,760   09/19/2022 Buy  97,422   12/08/2022 Buy 125,342
06/02/2022 Buy  61,506   09/20/2022 Buy  10,927   12/09/2022 Buy  43,512
06/06/2022 Buy  20,000   09/21/2022 Buy  25,711   12/12/2022 Buy  62,205
06/08/2022 Buy  114,527   09/22/2022 Buy  50,924   12/13/2022 Buy 160,176
06/09/2022 Buy  38,112   09/23/2022 Buy  1,300   12/14/2022 Buy  42,952
06/14/2022 Buy  58,933   09/26/2022 Buy  5,370   01/06/2023 Buy 104,494
06/21/2022 Buy  72,925   09/27/2022 Buy  24,013   01/09/2023 Buy  35,873
06/22/2022 Buy  35,794   09/28/2022 Buy  102,204   01/10/2023 Buy  18,173
06/23/2022 Buy  105,000   09/29/2022 Buy  50,000   01/11/2023 Buy  40,046
06/24/2022 Buy  38,090   09/30/2022 Buy  50,000   01/12/2023 Buy  500
06/28/2022 Buy  2,258   10/03/2022 Buy  1,230   01/23/2023 Buy  10,000
07/01/2022 Sell  (6,000)   10/04/2022 Buy  52,033   01/31/2023 Buy  13
07/06/2022 Buy  2,860   10/05/2022 Buy  61,479   02/03/2023 Buy  10,000
07/08/2022 Buy  6,027   10/06/2022 Buy  1,900   02/23/2023 Buy  3,500
07/11/2022 Buy  105,857   10/07/2022 Buy  20,000   02/24/2023 Buy  59,458
07/12/2022 Buy  79,266   10/10/2022 Buy  91,264   02/28/2023 Buy  3,409
07/13/2022 Buy  38,591   10/11/2022 Buy  23,107   03/01/2023 Buy 133,849
07/15/2022 Buy  55,412   10/13/2022 Buy  343,200   03/02/2023 Buy 153,341
07/18/2022 Buy  75,442   10/14/2022 Buy  24,866   03/03/2023 Buy 143,385
07/19/2022 Buy  17,332   10/17/2022 Buy  200,302   03/06/2023 Buy  34,088
07/20/2022 Buy  76,014   10/18/2022 Buy  116,947   03/07/2023 Buy  40,121
07/22/2022 Buy  10,000   10/19/2022 Buy  131,445   03/08/2023 Buy 137,280
07/25/2022 Buy  43,145   10/20/2022 Buy  86,926   03/09/2023 Buy 244,027
07/27/2022 Buy  72,328   10/21/2022 Buy  117,983   03/10/2023 Buy 413,078
07/28/2022 Buy  91,103   10/24/2022 Buy  43,378   03/13/2023 Buy 359,366
07/29/2022 Buy  48,915   10/25/2022 Buy  5,503   03/14/2023 Buy  55,185
08/01/2022 Buy  37,859   10/26/2022 Buy  35,388   03/15/2023 Sell  (32)
08/02/2022 Buy  55,295   10/27/2022 Buy  175,563   03/15/2023 Buy  5,248
08/05/2022 Buy  19,899   10/28/2022 Buy  106,049   03/16/2023 Buy  86,656
08/08/2022 Buy  55,542   10/31/2022 Buy  190,008   03/17/2023 Buy  10,966
08/09/2022 Buy  64,367   11/03/2022 Buy  61,646   03/20/2023 Buy 161,496
08/10/2022 Buy  69,135   11/04/2022 Buy  8,199   03/21/2023 Buy  87,947
08/12/2022 Buy  116,062   11/07/2022 Buy  80,668   03/22/2023 Buy  54,756
08/15/2022 Buy  57,789   11/08/2022 Buy  7,425   03/23/2023 Buy 197,451
08/16/2022 Buy  102,239   11/09/2022 Buy  100,000   03/24/2023 Buy  26,116
08/18/2022 Buy  32,042   11/10/2022 Buy  26,821   03/27/2023 Buy 102,148
08/23/2022 Buy  47,850   11/11/2022 Buy  208   03/28/2023 Buy  2,222
08/25/2022 Buy  76,453   11/14/2022 Buy  64,445   03/29/2023 Buy 146,191
08/26/2022 Buy  39,932   11/15/2022 Buy  81,461   03/30/2023 Buy  12,766

 

21 

 

03/31/2023 Buy  8   06/27/2023 Buy  52,523   11/01/2023 Buy  53,674
04/05/2023 Buy  192,905   06/28/2023 Buy  49,903   11/02/2023 Buy 146,580
04/06/2023 Buy  31,773   06/30/2023 Buy  41,361   11/03/2023 Buy 129,364
04/12/2023 Buy  20,000   07/06/2023 Buy  21,823   11/06/2023 Buy  7,210
04/13/2023 Buy  31,001   08/18/2023 Buy  12,498   11/07/2023 Buy  15,015
04/14/2023 Buy  12,260   08/21/2023 Buy 243,551   11/08/2023 Buy 302,069
04/17/2023 Buy  11,497   08/23/2023 Buy  97,606   11/09/2023 Buy 141,334
04/18/2023 Buy  34,544   08/24/2023 Buy  54,411   11/10/2023 Buy  42,717
04/19/2023 Buy  35,102   08/25/2023 Buy 136,493   11/13/2023 Buy 301,375
04/20/2023 Buy  173,904   08/28/2023 Buy  6,542   11/14/2023 Buy 102,638
04/21/2023 Buy  304,574   08/29/2023 Buy  92,581   11/15/2023 Buy 189,575
04/24/2023 Buy  24,503   08/30/2023 Buy  54,302   11/16/2023 Buy 122,114
04/25/2023 Buy  52,647   08/31/2023 Buy  57,268   11/17/2023 Buy  82,864
04/26/2023 Buy  187,950   09/05/2023 Buy  11,945   11/20/2023 Buy 317,592
04/27/2023 Buy  65,194   09/07/2023 Buy  22,519   11/21/2023 Buy 133,562
05/01/2023 Buy  58,063   09/08/2023 Buy 138,136   11/22/2023 Buy  37,592
05/02/2023 Buy  36,195   09/12/2023 Buy  39,924   11/24/2023 Buy  2
05/03/2023 Buy  4,395   09/13/2023 Buy  52,525   11/27/2023 Buy 342,147
05/04/2023 Buy  66,708   09/14/2023 Buy  86,065   11/28/2023 Buy  32,304
05/05/2023 Buy  49,711   09/15/2023 Buy  77,292   11/29/2023 Buy 234,871
05/08/2023 Buy  66,388   09/18/2023 Buy  6,309   11/30/2023 Buy 172,470
05/09/2023 Buy  45,322   09/20/2023 Buy  1,271   12/01/2023 Buy  62,142
05/10/2023 Buy  121,569   09/21/2023 Buy  16,520   12/04/2023 Buy 113,563
05/11/2023 Buy  40,725   09/22/2023 Buy  600   12/05/2023 Buy 366,218
05/12/2023 Buy  120,641   09/25/2023 Buy  74,372   12/06/2023 Buy  77,203
05/15/2023 Buy  21,659   09/27/2023 Buy 442,590   12/07/2023 Buy 176,434
05/16/2023 Buy  64,762   09/28/2023 Buy 197,046   12/08/2023 Buy 148,832
05/17/2023 Buy  78,467   09/29/2023 Buy 133,755   12/11/2023 Buy 133,259
05/18/2023 Buy  37,013   10/02/2023 Buy  88,457   12/12/2023 Buy  96,770
05/19/2023 Buy  34,855   10/03/2023 Buy  16,349   12/13/2023 Buy 321,840
05/23/2023 Buy  325,623   10/04/2023 Buy 194,681   12/14/2023 Buy 173,802
05/24/2023 Buy  87,074   10/05/2023 Buy 105,663   12/15/2023 Buy  50,086
05/25/2023 Buy  22,303   10/06/2023 Buy 145,133   12/18/2023 Buy 139,570
05/26/2023 Buy  50,026   10/09/2023 Buy  30,730   12/19/2023 Buy 488,281
05/30/2023 Buy  241,969   10/10/2023 Buy 103,294   12/20/2023 Buy 167,468
05/31/2023 Buy  31,687   10/11/2023 Buy  77,970   12/21/2023 Buy  72,840
06/01/2023 Buy  25,048   10/12/2023 Buy 225,565   12/22/2023 Buy  34,324
06/05/2023 Buy  18,414   10/13/2023 Buy  42,885   12/26/2023 Buy 164,459
06/07/2023 Buy  50,215   10/16/2023 Buy  322,194   12/27/2023 Buy 235,095
06/09/2023 Buy  3,617   10/17/2023 Buy  200,991   12/28/2023 Buy 299,702
06/12/2023 Buy  4,792   10/18/2023 Buy  163,226   12/29/2023 Buy  36,118
06/13/2023 Buy  71,169   10/19/2023 Buy  186,221   01/02/2024 Buy 114,600
06/14/2023 Buy  24,513   10/20/2023 Buy  10,017   01/03/2024 Buy  58,164
06/15/2023 Buy  2,126   10/23/2023 Buy  100,000   01/04/2024 Buy  2,885
06/16/2023 Buy  14,369   10/24/2023 Buy  79,712   01/05/2024 Buy 38,697
06/20/2023 Buy  206,504   10/25/2023 Buy  40,552   01/09/2024 Buy 73,695
06/21/2023 Buy  42,658   10/26/2023 Buy  76,041   01/10/2024 Buy 42,965
06/22/2023 Buy  193,520   10/27/2023 Buy  30,385   01/11/2024 Buy 33,594
06/23/2023 Buy  38,175   10/30/2023 Buy  79,757   01/12/2024 Buy  21,554
06/26/2023 Buy  50,000   10/31/2023 Buy 127,999   01/16/2024 Buy  81,123

 

22 

 

 

01/17/2024 Buy  106,270                
01/18/2024 Buy  54,851                
01/19/2024 Buy  11,171                
01/22/2024 Buy  27,762                
01/23/2024 Buy  76,418                
01/24/2024 Buy  140,942                
01/25/2024 Buy  209,234                
01/26/2024 Buy  197,651                
01/29/2024 Buy  140,097                
01/31/2024 Buy  72,027                
02/01/2024 Buy  636                
02/02/2024 Buy  66,190                
02/05/2024 Buy  137,156                
02/06/2024 Buy  82,389                
02/07/2024 Buy  98,842                
02/08/2024 Buy  47,952                
02/09/2024 Buy  67,852                
02/12/2024 Buy  138,735                
02/13/2024 Buy  184,717                
02/14/2024 Buy  35,287                
02/15/2024 Buy  65,034                
02/16/2024 Buy  25,699                
02/20/2024 Buy  91,079                
02/21/2024 Buy  23,672                
02/22/2024 Buy  43,233                
02/23/2024 Buy  65,882                
02/26/2024 Buy  246,840                
02/27/2024 Buy  278,093                
02/28/2024 Buy  34,662                
02/29/2024 Buy  49,946                
03/01/2024 Buy  133,395                
03/06/2024 Buy  53,685                
03/07/2024 Buy  36,450                
03/08/2024 Buy  40,028                
03/11/2024 Buy  73,028                
03/12/2024 Buy  1,000                
03/18/2024 Buy  77,855                
03/19/2024 Buy  51,583                
03/20/2024 Buy  107,194                
03/21/2024 Buy  97,886                
03/22/2024 Buy  35,187                
03/25/2024 Buy  40,881                
03/26/2024 Buy  98,314                
03/27/2024 Buy  110,651                
03/28/2024 Buy  203,385                
04/01/2024 Buy  55,980                
                     
                     
                     
                     

 

 

23 

 

IMPORTANT

 

Tell your Board what you think! YOUR VOTE IS VERY IMPORTANT, no matter how many or how few shares you own. Please give us your vote FORthe Nominees by taking three steps:

 

  SIGNING the enclosed GOLD proxy card,
     
  DATING the enclosed GOLD proxy card, and
     
  MAILING the enclosed GOLD proxy card TODAY in the envelope provided (no postage is required if mailed in the United States).

 

If any of your shares are held in the name of a broker, bank, bank nominee or other institution, only it can vote your shares and only upon receipt of your specific instructions. Depending upon your broker or custodian, you may be able to vote either by toll-free telephone or by the Internet. You may also vote by signing, dating and returning the enclosed GOLD voting instruction form in the postage-paid envelope provided, and to ensure that your shares are voted, you should also contact the person responsible for your account and give instructions for a GOLD voting instruction form to be issued representing your shares.

 

By returning the GOLD proxy card, you are authorizing Saba to vote on your behalf, and if you do not indicate how you would like to vote, your vote will be counted “FOR ALL” of the Nominees in Proposal 1 and “FOR” Proposal 2.

 

After signing the enclosed GOLD proxy card, DO NOT SIGN OR RETURN THE FUND’S WHITE PROXY CARD UNLESS YOU INTEND TO CHANGE YOUR VOTE, because only your latest dated proxy card will be counted.

 

If you have previously signed, dated and returned a white proxy card to the Fund, you have every right to change your vote. Only your latest dated proxy card will count. You may revoke any proxy card already sent to the Fund by signing, dating and mailing the enclosed GOLD proxy card in the postage-paid envelope provided or by voting by telephone or Internet. Any proxy may be revoked at any time prior to the Annual Meeting by delivering a written notice of revocation or a later dated proxy for the Annual Meeting to the secretary of the Fund or by voting in person at the Annual Meeting. Attendance at the Annual Meeting will not in and of itself constitute a revocation.

 

If you have any questions concerning this Proxy Statement, would like to request additional copies of this Proxy Statement, or need help voting your shares, please contact our proxy solicitor:

 

 



19 Old Kings Highway S., Suite 130

Darien, CT 06820
Shareholders Call Toll-Free at: (877) 972-0090

E-mail: Saba@investor-com.com

 

24 

 

Form of GOLD Proxy Card

BlackRock ESG Capital Allocation Term Trust

Proxy Card for 2024 Annual Meeting of Shareholders (the “Annual Meeting”)

 

THIS PROXY SOLICITATION IS BEING MADE BY SABA CAPITAL MANAGEMENT, L.P., SABA CAPITAL MASTER FUND, LTD., Boaz R. Weinstein (COLLECTIVELY, “SABA”) AND THE INDIVIDUALS NAMED IN PROPOSAL 1

 

THE BOARD OF TRUSTEES (THE “BOARD”) OF BLACKROCK ESG CAPITAL ALLOCATION TERM TRUST IS NOT SOLICITING THIS PROXY

 

The undersigned appoints Michael D’Angelo, Paul Kazarian, Eleazer Klein, Abraham Schwartz, Pierre Weinstein and John Grau and each of them, attorneys and agents with full power of substitution to vote all shares of BlackRock ESG Capital Allocation Term Trust, a Maryland statutory trust and a closed-end management investment company registered under the Investment Company Act of 1940, as amended (the “Fund”), that the undersigned would be entitled to vote at the Annual Meeting, including at any adjournments or postponements thereof, with all powers that the undersigned would possess if personally present, upon and in respect of the instructions indicated herein, with discretionary authority, subject to applicable law, as to any and all other matters that may properly come before the meeting or any adjournment, postponement, or substitution thereof that are unknown to us a reasonable time before this solicitation.

 

The undersigned hereby revokes any other proxy or proxies heretofore given to vote or act with respect to said shares, and hereby ratifies and confirms all action the herein named attorneys and proxies, their substitutes, or any of them may lawfully take by virtue hereof. This proxy will be valid until the sooner of one year from the date indicated on the reverse side and the completion of the Annual Meeting (including any adjournments or postponements thereof).

 

With respect to the Proposals, if this proxy is signed, dated and returned, it will be voted in accordance with your instructions. If you do not specify how the proxy should be voted, this proxy will be voted “FOR ALL” of the Nominees (as defined below) in Proposal 1 and “FOR” Proposal 2. None of the matters currently intended to be acted upon pursuant to this proxy are conditioned on the approval of other matters.

 

INSTRUCTIONS: FILL IN VOTING BOXES nIN BLACK OR BLUE INK

 

*Abstentions will be treated as shares that are present and entitled to vote and therefore will count as votes against the proposals below.

We recommend that you vote “FOR ALL” of the Nominees in Proposal 1:

 Proposal 1 – Election at the Annual Meeting of the individuals nominated by Saba to serve as Class II trustees (the “Class II Nominees”) and the individuals nominated by Saba to serve as successors to the Fund’s Class I holdover trustees due to the Fund not having held an annual shareholder meeting in 2023 (the “Class I Nominees”, and together with the Class II Nominees, the “Nominees”).

 

FOR ALL AGAINST ALL ABSTAIN FOR ALL*
q q q

 

Nominees: FOR AGAINST ABSTAIN*
Ilya Gurevich (Class II) q q q
Shaver Jeffries (Class II) q q q
Jennifer Raab (Class II) q q q
David Littlewood (Class I) q q q
David Locala (Class I) q q q
Athanassios Diplas (Class I) q q q
Alexander Vindman (Class I) q q q

 

 

 

We recommend that you vote “FOR” Proposal 2:

Proposal 2 – Termination of the investment management agreement between the Fund and BlackRock Advisors, LLC, the Fund’s investment manager, the form of which is attached to the Fund’s Form N-2 filed with the Securities and Exchange Commission on August 17, 2021, as since amended or novated.

 

FOR AGAINST ABSTAIN*
q q q

 

 

     
Signature (Capacity)   Date
     
Signature (Joint Owner) (Capacity/Title)   Date
     
NOTE: Please sign exactly as your name(s) appear(s) on stock certificates or on the label affixed hereto.  When signing as attorney, executor, administrator or other fiduciary, please give full title as such.  Joint owners must each sign personally.  ALL HOLDERS MUST SIGN.  If a corporation or partnership, please sign in full corporate or partnership name by an authorized officer and give full title as such.

 

PLEASE SIGN, DATE AND PROMPTLY RETURN THIS PROXY IN THE ENCLOSED RETURN ENVELOPE THAT IS POSTAGE PREPAID IF MAILED IN THE UNITED STATES.